Stifel Maintains Buy on Guardant Health, Raises Price Target to $180

Benzinga Newsdesk www.benzinga.com Positive 81.5%

Neg 0% Neu 0% Pos 81.5%

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $130 to $180.